Single dose pharmacokinetics and pharmacodynamics of oxazepam in normal and renal dysfunction rats

Kalpana Srivastava, Tomomi Hatanaka, Tetsuya Aiba, Kazunori Katayama, Tamotsu Koizumi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The purpose of this work was to investigate the disposition characteristics and pharmacodynamics of a benzodiazepine, oxazepam, in renal dysfunction rats. For the in vivo experiment, normal and renal dysfunction rats were given 40 mg/kg of oxazepam as the bolus dose. A quantitative electroencephalographic (EEG) method was used as the surrogate measure of the pharmacological response. The oxazepam concentration in plasma and cerebrospinal fluid (CSF) was assayed by the HPLC method. The steady-state volume of distribution and clearance based on total and unbound plasma did not change in renal dysfunction rats. Amplitude changes in the EEG induced by oxazepam in normal and renal dysfunction rats were characterized by a log- concentration response model or sigmoidal E(max) model. The pharmacodynamic parameters from these models were not altered in renal dysfunction. In in vitro binding studies for γ-aminobutyric acid (GABA)-benzodiazepine receptor complex, the oxazepam-induced effect was not potentiated by the plasma dialysate from renal dysfunction rats. Thus, it was suggested that the brain sensitivity to benzodiazepines was not altered in renal insufficiency.

Original languageEnglish
Pages (from-to)627-632
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume22
Issue number6
Publication statusPublished - Jun 1999
Externally publishedYes

Fingerprint

Oxazepam
Pharmacokinetics
Kidney
Benzodiazepines
Aminobutyrates
Dialysis Solutions
GABA-A Receptors
Renal Insufficiency
Cerebrospinal Fluid
High Pressure Liquid Chromatography
Pharmacology
Brain

Keywords

  • γ- aminobutyric acid(A) (GABA(A)) receptor
  • Oxazepam
  • Pharmacodynamics
  • Pharmacokinetics
  • Rat
  • Renal dysfunction

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Single dose pharmacokinetics and pharmacodynamics of oxazepam in normal and renal dysfunction rats. / Srivastava, Kalpana; Hatanaka, Tomomi; Aiba, Tetsuya; Katayama, Kazunori; Koizumi, Tamotsu.

In: Biological and Pharmaceutical Bulletin, Vol. 22, No. 6, 06.1999, p. 627-632.

Research output: Contribution to journalArticle

Srivastava, Kalpana ; Hatanaka, Tomomi ; Aiba, Tetsuya ; Katayama, Kazunori ; Koizumi, Tamotsu. / Single dose pharmacokinetics and pharmacodynamics of oxazepam in normal and renal dysfunction rats. In: Biological and Pharmaceutical Bulletin. 1999 ; Vol. 22, No. 6. pp. 627-632.
@article{a85773e995c24439b63cee3b497a3dfb,
title = "Single dose pharmacokinetics and pharmacodynamics of oxazepam in normal and renal dysfunction rats",
abstract = "The purpose of this work was to investigate the disposition characteristics and pharmacodynamics of a benzodiazepine, oxazepam, in renal dysfunction rats. For the in vivo experiment, normal and renal dysfunction rats were given 40 mg/kg of oxazepam as the bolus dose. A quantitative electroencephalographic (EEG) method was used as the surrogate measure of the pharmacological response. The oxazepam concentration in plasma and cerebrospinal fluid (CSF) was assayed by the HPLC method. The steady-state volume of distribution and clearance based on total and unbound plasma did not change in renal dysfunction rats. Amplitude changes in the EEG induced by oxazepam in normal and renal dysfunction rats were characterized by a log- concentration response model or sigmoidal E(max) model. The pharmacodynamic parameters from these models were not altered in renal dysfunction. In in vitro binding studies for γ-aminobutyric acid (GABA)-benzodiazepine receptor complex, the oxazepam-induced effect was not potentiated by the plasma dialysate from renal dysfunction rats. Thus, it was suggested that the brain sensitivity to benzodiazepines was not altered in renal insufficiency.",
keywords = "γ- aminobutyric acid(A) (GABA(A)) receptor, Oxazepam, Pharmacodynamics, Pharmacokinetics, Rat, Renal dysfunction",
author = "Kalpana Srivastava and Tomomi Hatanaka and Tetsuya Aiba and Kazunori Katayama and Tamotsu Koizumi",
year = "1999",
month = "6",
language = "English",
volume = "22",
pages = "627--632",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "6",

}

TY - JOUR

T1 - Single dose pharmacokinetics and pharmacodynamics of oxazepam in normal and renal dysfunction rats

AU - Srivastava, Kalpana

AU - Hatanaka, Tomomi

AU - Aiba, Tetsuya

AU - Katayama, Kazunori

AU - Koizumi, Tamotsu

PY - 1999/6

Y1 - 1999/6

N2 - The purpose of this work was to investigate the disposition characteristics and pharmacodynamics of a benzodiazepine, oxazepam, in renal dysfunction rats. For the in vivo experiment, normal and renal dysfunction rats were given 40 mg/kg of oxazepam as the bolus dose. A quantitative electroencephalographic (EEG) method was used as the surrogate measure of the pharmacological response. The oxazepam concentration in plasma and cerebrospinal fluid (CSF) was assayed by the HPLC method. The steady-state volume of distribution and clearance based on total and unbound plasma did not change in renal dysfunction rats. Amplitude changes in the EEG induced by oxazepam in normal and renal dysfunction rats were characterized by a log- concentration response model or sigmoidal E(max) model. The pharmacodynamic parameters from these models were not altered in renal dysfunction. In in vitro binding studies for γ-aminobutyric acid (GABA)-benzodiazepine receptor complex, the oxazepam-induced effect was not potentiated by the plasma dialysate from renal dysfunction rats. Thus, it was suggested that the brain sensitivity to benzodiazepines was not altered in renal insufficiency.

AB - The purpose of this work was to investigate the disposition characteristics and pharmacodynamics of a benzodiazepine, oxazepam, in renal dysfunction rats. For the in vivo experiment, normal and renal dysfunction rats were given 40 mg/kg of oxazepam as the bolus dose. A quantitative electroencephalographic (EEG) method was used as the surrogate measure of the pharmacological response. The oxazepam concentration in plasma and cerebrospinal fluid (CSF) was assayed by the HPLC method. The steady-state volume of distribution and clearance based on total and unbound plasma did not change in renal dysfunction rats. Amplitude changes in the EEG induced by oxazepam in normal and renal dysfunction rats were characterized by a log- concentration response model or sigmoidal E(max) model. The pharmacodynamic parameters from these models were not altered in renal dysfunction. In in vitro binding studies for γ-aminobutyric acid (GABA)-benzodiazepine receptor complex, the oxazepam-induced effect was not potentiated by the plasma dialysate from renal dysfunction rats. Thus, it was suggested that the brain sensitivity to benzodiazepines was not altered in renal insufficiency.

KW - γ- aminobutyric acid(A) (GABA(A)) receptor

KW - Oxazepam

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Rat

KW - Renal dysfunction

UR - http://www.scopus.com/inward/record.url?scp=0033010405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033010405&partnerID=8YFLogxK

M3 - Article

C2 - 10408239

AN - SCOPUS:0033010405

VL - 22

SP - 627

EP - 632

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 6

ER -